Apellis Pharmaceuticals Inc. shares (APLS) jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc. (4503.TO), on Monday released results of a trial of Izervay as a treatment for geographic atrophy, a form of age-related macular degeneration. Based on the new data, Izervay's "efficacy is totally unclear and safety got worse," Raymond James analysts wrote in a note Monday. The analysts maintained a strong buy rating on shares of Apellis, whose geographic atrophy treatment Syfovre was approved by the U.S. Food and Drug Administration early this year. Syfovre has also been dogged by safety concerns, but Apellis late last month identified a certain type of needle as a potential cause of inflammation of retinal vessels seen as a rare but serious side effect of the eye treatment. Apellis shares have dropped 9% in the year to date, while the S&P 500 has gained 16%.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.